December 7, 2015
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President & Chief Executive Officer

Start of Japan Phase I Combination Clinical Trial of Oral Rigosertib and Azacytidine in Higher-risk MDS

TOKYO, Japan, December 7, 2015 --- SymBio Pharmaceuticals Limited (Headquarters: Tokyo, "SymBio") announced today the start of the Phase I clinical trial in Japan for oral rigosertib (SyB C-1101, oral formulation) combined with azacytidine (Vidaza: currently marketed by Nippon Shinyaku Co., Ltd.) in higher-risk myelodysplastic syndrome (MDS) patients ("Phase I Combination Trial").

SymBio has completed its Phase I clinical trial in Japan for oral rigosertib as a mono therapy in transfusion-dependent lower-risk MDS patients on June 26, 2015 and upon completion of this Phase I Combination Trial, SymBio will consider participating in a global Phase III trial which its US partner, Onconova Therapeutics, Inc. (Headquarters: Newtown, PA, "Onconova") plans to initiate. According to Onconova, the Phase II trial enrollment is complete and the company plans to present these study results at the 57th ASH Meeting currently held from Dec. 5, 2015 to Dec. 8, 2015.

Start of the Phase I Combination Trial will not impact the Company's financial forecast for FY2015.

[Contact]
Investor Relations
Tel: +81 (0)3 5472 1125

About Myelodysplastic Syndrome (MDS)

MDS patients often require frequent blood transfusions due to the development of severe anemia (decrease in number of red blood cells), with a high rate of progression to acute myelogenous leukemia (AML). There are an estimated 11,000 MDS patients in Japan alone, with the number of cases expected to increase as the population ages. MDS and AML are widely recognized as blood disorders that are difficult to manage given the

limited therapeutic options available for patients, particularly for patients who have a drug-resistant form of the disease. A high unmet medical need clearly exists for the establishment of new effective therapies to treat both lower- and higher-risk MDS.

About azacytidine (Vidaza: currently marketed by Nippon Shinyaku Co., Ltd) Vidaza was approved in 2011, showing overall survival in the Phase III trial for the first time, and is currently used by MDS patients having difficulties in hematopoietic stem cell transplantation.

About Onconova Therapeutics, Inc.

Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer. Onconova's clinical and pre-clinical stage drug development candidates are derived from its extensive chemical library and are designed to work against specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells. In addition to rigosertib, Onconova's most advanced drug candidate under development, two other drug candidates are in clinical trials and several other compounds in the pre-clinical stage of development. For more information, please visit http://www.onconova.com.

About SymBio Pharmaceuticals Limited

SymBio Pharmaceuticals Ltd. was established in March, 2005, by Fuminori Yoshida who previously served concurrently as Corporate VP of Amgen Inc. and founding President of Amgen Japan. The company's underlying corporate mission is to "deliver hope to patients in need" as it aspires to be a leading specialty pharmaceutical company in Asia Pacific dedicated to addressing underserved medical needs with main therapeutic focus in oncology, hematology and pain management.